ADA meeting: Clean CV data strengthen Januvia and Lyxumia
This article was originally published in Scrip
Reassuring cardiovascular outcomes data from the TECOS study of Merck & Co's Januvia (sitagliptin) should reinforce the market leadership of the DPP-IV inhibitor after its rivals' CVOT studies saw an unexpected signal for heart failure hospitalization.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.